Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib
about
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerMultidrug Resistance Proteins (MRPs) and Cancer TherapyModulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening.ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasWhat is known about melatonin, chemotherapy and altered gene expression in breast cancerRecent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionGeneration and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.Development of the rat model of lapatinib-induced diarrhoea.Controlling the Mdm2-Mdmx-p53 Circuit.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsClinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast CancerLapatinib - Member of a New Generation of ErbB-Targeting Drugs.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerPresent and future evolution of advanced breast cancer therapy.PET of EGFR expression with an 18F-labeled affibody molecule.Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerTargeting the tumor microenvironment: focus on angiogenesis.In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain.Lapatinib: the evidence for its therapeutic value in metastatic breast cancer.The use of novel selectivity metrics in kinase research.A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrheaIs the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.Leptomeningeal Metastasis: Challenges in Diagnosis and TreatmentMicroRNA-205 increases the sensitivity of docetaxel in breast cancer.A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia.Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3The molecular genetics of breast cancer and targeted therapyDual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancerMechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation.The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma.
P2860
Q26772969-A06601D1-95A0-4D20-A753-E78C2652B519Q26992204-60ADCCE7-5808-43A9-8A00-A3163FAA97F2Q28655621-57546AE3-922C-48B4-8B7D-A60204D57242Q30393891-8C7BD381-804B-4157-92CE-98C5DB64CA76Q30457869-97FAE1EB-8EA3-42A4-8607-F1C8CD3B7F91Q33273701-427154D6-72F8-4307-94E0-1523EC69084CQ33597963-75997EA2-456A-4050-BD67-E19FEECE9313Q33633267-FDBA1132-9D38-4C99-84CF-23F1AE975AD3Q33644407-D6E53B50-7F3E-44EF-8F9B-699F8F4D931CQ33684453-BE759B26-216C-43F9-94CF-1D4ED1880284Q33829405-39CB3C39-99EB-4245-80CC-1B1516142565Q33907971-7861A62E-F6EF-433B-AB40-6C3A17DB090CQ33999288-E6A8DCE3-D7E2-4E08-9559-A61B91F01DDFQ34011009-861A6AFF-DC85-43CE-B9A7-6DD5DDC3C7CAQ34023704-C4F1D364-E9BD-4909-9A36-95DF125D4448Q34095748-FC533D37-2D9C-40C4-857E-4FEBF7D7C69CQ34096228-ECB6F3B0-C6EB-4A5E-A9C6-B232E54649E1Q34193975-31E84A40-29CF-47FD-896C-1A5AE3C9206AQ34268618-225ACF34-E689-4E3D-B43E-A17BEED73C34Q34274925-93BEB0D5-D81A-4916-B0DF-5F0837D987C1Q34429075-0514F387-229C-4095-BADF-7B80B9BEB4A1Q34908845-BED95E2B-2743-4CB1-8D2E-C70FC494CD75Q34978404-8B04F451-C399-4643-A5BE-0AA51A5549CAQ35184806-E03A773E-9948-4B8D-8A40-9188F106589AQ35803276-6F4A3E8C-3AF1-4B56-9FA3-B75AB919ABE3Q35876373-6950F32B-26CC-48C7-B538-70CA0A2F5B95Q36240657-99489145-9FBB-4430-B785-2CF8C8EE8D12Q36290627-27BF6CEC-C416-43CA-974F-EC0CC5678390Q36384340-D8A645A9-F326-4552-9E89-C502BA91B505Q36440625-5911DB8A-326E-4B21-B016-C13C0105A835Q36469191-F316AF8C-25E4-4B96-AFD9-74CED1730B7EQ36523888-F974C4D5-1D8B-4019-95EF-4E8E1A89EEFAQ36642955-CD206B52-DCE3-4BE1-9F5B-335B3D907EA6Q36669662-4423E672-AA36-46C8-913B-66E674D1D4ECQ36670740-F23978A7-5C0D-46EB-888E-54831DAE120AQ36793441-9566DE02-9419-4CBF-96EF-C659ED3F13A3Q37290512-DA8BCA0A-0D05-46E2-A650-1BE5DFA9D8BCQ37344085-9A1C7AAA-797E-42BA-A689-38DF0DA14039Q37633691-70B2855D-5EF4-4990-BC73-7692541A5361Q37667777-E03FCBEE-E0B2-4CAA-850B-2D64D6D5DFE4
P2860
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib
description
2004 nî lūn-bûn
@nan
2004 թուականին հրատարակուած գիտական յօդուած
@hyw
2004 թվականին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@ast
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@en
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@nl
type
label
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@ast
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@en
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@nl
prefLabel
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@ast
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@en
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@nl
P1433
P1476
Dual kinase inhibition in the ...... GFR/ErbB-2 inhibitor lapatinib
@en
P2093
Howard A Burris
P407
P478
P577
2004-01-01T00:00:00Z